We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.3%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.83B
AUM Growth
-$193M
Cap. Flow
-$2.01B
Cap. Flow %
-41.54%
Top 10 Hldgs %
42.39%
Holding
141
New
14
Increased
13
Reduced
19
Closed
37

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$95.6M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$71.9M
3
AMED
Amedisys
AMED
+$70M
4
PCVX icon
Vaxcyte
PCVX
+$27.5M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$24.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$94.9M
2
BIIB icon
Biogen
BIIB
+$88.1M
3
AERI
Aerie Pharmaceuticals
AERI
+$73.5M
4
LUNG icon
Pulmonx
LUNG
+$62M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$55.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.42%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
76
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$24.1K ﹤0.01%
166,666
– –
EUCRW
77
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$18.5K ﹤0.01%
333,333
– –
SRZNW icon
78
Surrozen Inc Warrant
SRZNW
$75.6K
$9.18K ﹤0.01%
166,666
– –
MTACU
79
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$10 ﹤0.01%
1
– –
EUCRU
80
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$10 ﹤0.01%
1
– –
ADCT icon
81
ADC Therapeutics
ADCT
$145M
– –
-2,390,297
Closed -$11.5M
ANTX icon
82
AN2 Therapeutics
ANTX
$178M
– –
-716,538
Closed -$12.5M
BIIB icon
83
Biogen
BIIB
$29.5B
– –
-330,000
Closed -$88.1M
CYTK icon
84
Cytokinetics
CYTK
$10.9B
– –
-813,112
Closed -$39.4M
DCTH icon
85
Delcath Systems
DCTH
$412M
– –
-486,068
Closed -$1.55M
GILD icon
86
Gilead Sciences
GILD
$162B
– –
-1,537,539
Closed -$94.9M
HOWL icon
87
Werewolf Therapeutics
HOWL
$22M
– –
-958,125
Closed -$4.32M
INZY
88
DELISTED
Inozyme Pharma
INZY
– –
-2,090,436
Closed -$5.6M
LUNG icon
89
Pulmonx
LUNG
$51.5M
– –
-3,720,901
Closed -$62M
MOH icon
90
Molina Healthcare
MOH
$10.4B
– –
-75,000
Closed -$24.7M
PACB icon
91
Pacific Biosciences
PACB
$422M
– –
-2,021,000
Closed -$11.7M
PHAT icon
92
Phathom Pharmaceuticals
PHAT
$953M
– –
-2,414,897
Closed -$26.8M
PHVS icon
93
Pharvaris
PHVS
$2.37B
– –
-1,104,552
Closed -$8.47M
PROF
94
Profound Medical
PROF
$266M
– –
-732,543
Closed -$2.96M
QSI icon
95
Quantum-Si Incorporated
QSI
$171M
– –
-1,400,000
Closed -$3.85M
RCKT icon
96
Rocket Pharmaceuticals
RCKT
$355M
– –
-870,000
Closed -$13.9M
TGTX icon
97
TG Therapeutics
TGTX
$8.53B
– –
-2,677,500
Closed -$15.9M
TLSI icon
98
TriSalus Life Sciences
TLSI
$265M
– –
-999,999
Closed -$9.93M
VCEL icon
99
Vericel Corp
VCEL
$2.31B
– –
-484,947
Closed -$11.3M
VERV
100
DELISTED
Verve Therapeutics
VERV
– –
-750,000
Closed -$25.8M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2022 Portfolio in Review

As of Q4 2022, Deerfield Management held 141 positions worth $4.83B, down 3.8% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $2.01B in Q4 2022, closing 37 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $94.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Amylyx Pharmaceuticals worth $99.5M.

  • Deerfield Management's largest Q4 2022 buy was Amylyx Pharmaceuticals: 2,693,000 shares worth $99.5M.
  • Deerfield Management added most to Amedisys in Q4 2022, an estimated $70M increase.
  • Deerfield Management's biggest Q4 2022 reduction was Silk Road Medical, Inc. Common Stock, cutting an estimated $55.5M.
  • Deerfield Management fully exited Gilead Sciences in Q4 2022, selling an estimated $94.9M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.83B portfolio in Q4 2022.
  • Deerfield Management opened 14 new positions and closed 37 in Q4 2022.
  • Deerfield Management's portfolio value fell 3.8% quarter-over-quarter to $4.83B.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.